fk (Total 206 Patents Found)

Fk (206 Patents Found)
The invention relates to a new microorganism Streptomyces glaucescens MTCC 5115 and a process for producing the immunosuppressant agent, tacrolimus (FK-506) utilizing the new microorganism Streptomyces glaucescens MTCC 5115. The invention also relates to pharmaceutical compositions that include the tacrolimus (FK-5...
Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase....
A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 μg FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes reta...
Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase....
Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counter...
Il est possible d'utiliser des cellules hôtes comprenant des vecteurs de recombinaison codant la polykétide FK-520 synthase et des enzymes de modification de FK-520 pour produire le polykétide FK-520. Il est également possible de se servir de produits d'ADN de recombinaison comprenant un ou plusieurs domain...
本实用新型公开一种FK系列压接型辅助开关,包括基板;所述基板上设有接线端子;接线端子包括压片、定触片、接线框、铆钉、螺钉;所述定触片通过铆钉固接有接线框;所述接线框设有开口槽,该开口槽内容置有压片自由端;所述接线框下...
Die vorliegende Erfindung betrifft neue Flüssigkristallverbindungen, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Verwendung für optische, elektrooptische und elektronische Zwecke, insbesondere in Flüssigkristall (FK)-Medien und FK-Anzeigen, sowie diese enthaltende FK-Medien und FK-Anzeigen....
Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce ...
Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase....
L'invention concerne des procédés pour la synthèse de 42-hémiesters de rapamycine régiospécifiques et de 32-esters de FK-506 régiospécifiques avec des acides carboxyliques : on catalyse la réaction entre rapamycine ou FK-506 et un anhydride dicarboxylique ou un ester bifonctionnel activé d'acide dicar...
Procedimiento para la síntesis regioespecífica de un 42-hemiéster de rapamicina o un 32-hemiéster de FK- 506 con un ácido dicarboxílico, comprendiendo dicho procedimiento la etapa que consiste en hacer reaccionar una rapamicina o un FK-506 con un anhídrido dicarboxílico en presencia de una lipasa....
PURPOSE: To easily obtain all the diastereo-isomers being useful as a synthetic intermediate for an FK-506 immunosuppressant by reacting an epoxide with a prolinol propionamide in the presence of a specified compd. CONSTITUTION: A compd. of formula I (wherein P is an OH protective group being removable by cataly...
A new homogeneous cytosolic binding protein (FKBP-14.6 immunophilin) having a molecular weight of about 14.6 kDa (calculated from its amino acid composition), reversibly binds the immunosuppressive drugs FK-506, rapamycin or chemically related compounds, but not cyclosporine. The FKBP-14.6 protein has a pI of 6.5-7.5, ...
A compound of the formula ##STR1## is a novel immunosuppressant agent prepared by fermenting Steptomyces braeaensis subsp. pulcherrimus, ATCC 55150, or another compound of the formula I producing strain and extracting the compound of the formula I from the fermentation medium. The compound is useful in treating transpl...
A method and system for use in treating a patient with FK 506 to prevent an adverse immune response, either a rejection of a transplanted organ or an attack on the patient's body by its own immune system caused by an autoimmune disease, without unduly suppressing the ability of the patient's immune system to co...
Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone ...
A method and system for use in treating a patient with FK 506 to prevent an adverse immune response, either a rejection of a transplanted organ or an attack on the patient's body by its own immune system caused by an autoimmune disease, without unduly suppressing the ability of the patient's immune system to co...
Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce ...
New derivatives of FK 506 are disclosed. These new derivatives and other derivatives that are useful for determining the levels of FK 506 in a sample are also provided as are assay procedures and kits for use in determining the levels of FK 506 or other macrophilin binding substances in blood, particularly un-extracted...
Described is a new immunosuppressant, L-687,795, a C-13, C-15, C-31 trisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in prevent...
Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase....
A module and method of its production in which areal electronic components are formed. The module includes (a) a cover electrode covering the electronic components; (b) a flexibly deformable substrate; (c) a base electrode formed on the substrate; and (d) an optically active layer formed on the base electrode. The elec...
A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties....
Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase....
Heteroatom-contg. tetracyclic cpds. of formula (I) are new, where R1 is Me, Et, Pr or allyl; and R2 is opt. protected hydroxy or acyloxy. USE/ADVANTAGE - (I) have immunosuppressive and antiinflammatory activity, and may be used to treat resistance to organ transplantation, graft-versus-host disorders in bone marrow tra...
Macrolide compounds having the structure shown below ##STR1## wherein R 1 is hydroxy or protected hydroxy, R 2 is hydrogen, hydroxy or protected hydroxy, R 3 is methyl, ethyl, propyl or allyl, R 4 is hydroxy, methoxy or oxo, n is 1 or 2 and the symbol of a line and a dotted is a single bond or a double bond, provid...
Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone ...
3/23/89:F1 17915 TITLE OF THE INVENTION ABSTRACT OF THE DISCLOSURE A process is described for the improved synthesis of the optically pure C10-C18 fragment of the macrolide structure of the immunosuppressant FK-506. This compound is also useful as an intermediate for pr...
L'invention concerne des procédés pour la synthèse de 42-hémiesters de rapamycine régiospécifiques et de 32-esters de FK-506 régiospécifiques avec des acides carboxyliques : on catalyse la réaction entre rapamycine ou FK-506 et un anhydride dicarboxylique ou un ester bifonctionnel activé d'acide dicar...
Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce ...